QUALITY IN SPORT
eISSN 2450-3118 · Open Access · Peer-reviewed
apcz.umk.pl/QS Nicolaus Copernicus University in Toruń

SOBCZAK, Agata, KOWALCZYK, Maja, WOLFF, Magdalena, GŁUSZKIEWICZ, Lena, KREFT, Kalina and WALDMAN, Anna. Impact of pre-acclimatization and smart-monitoring technologies on safety and success on Everest- a narrative review. Quality in Sport. 2026;72:75416. https://doi.org/10.12775/QS.2026.72.75416

ARTICLE TIMELINE
Received: 17.08.2026. Revised: 30.08.2026. Accepted: 07.09.2026. Published: 16.09.2026.

The journal has been awarded 20 points in the parametric evaluation by the Polish Ministry of Higher Education and Science (Annex to the announcement of 05.01.2024, No. 32553). Unique Journal Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).
Punkty Ministerialne z 2019 – aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

Impact of pre-acclimatization and smart-monitoring technologies on safety and success on Everest- a narrative review.

Authors:

Agata Sobczak

University Clinical Center in Gdańsk

Dębinki 7, 80-952 Gdańsk, Poland

https://orcid.org/0009-0009-0396-3578, agata.mar.gawron@gmail.com

Maja Kowalczyk

Karol Marcinkowski University Hospital in Zielona Góra

Zyty 26 65-046 Zielona Góra, Poland

https://orcid.org/0009-0000-0074-1405, maja.u.kowalczyk@gmail.com

Lena Głuszkiewicz
University Clinical Center in Gdańsk
Dębinki 7, 80-952 Gdańsk, Poland
https://orcid.org/0009-0009-3627-0364, lgluszkiewicz@uck.gda.pl

Magdalena Wolff
Karol Marcinkowski University Hospital in Zielona Góra
Zyty 26, 65-046 Zielona Góra, Poland
https://orcid.org/0009-0003-8972-0273, magda.wolff@o2.pl

Kalina Kreft
Karol Marcinkowski University Hospital in Zielona Góra
Zyty 26, 65-046 Zielona Góra, Poland
https://orcid.org/0009-0001-9584-7305 , kreft.kalina@gmail.com

Anna Waldman
Poznan University of Medical Sciences, Collegium Maius
Aleksandra Fredry 10, 61-701 Poznań, Poland
https://orcid.org/0009-0001-2332-1814, anna.waldman29@gmail.com

Corresponding Author
Agata Sobczak agata.mar.gawron@gmail.com

Abstract

Background: Mount Everest represents the ultimate human physiological frontier. Traditionally restricted to elite athletes with exceptional natural tolerance to hypoxia, high-altitude mountaineering has undergone a paradigm shift driven by technological innovation. These advancements act as a "great equalizer," allowing individuals with limited experience or physiological adaptability to attempt the summit with higher success rates.

Objective: This narrative review synthesizes contemporary evidence (2012–2026) regarding how pre-acclimatization and smart-monitoring technologies function as core drivers of this accessibility shift.

Methods: A targeted search of PubMed, Scopus, and Google Scholar was performed using Boolean operators. Twenty-one key publications were qualitatively synthesized, focusing on hypoxia conditioning (HC) protocols, wearable physiological telemetry (SpO2, ECG), and expedition statistics derived from the Himalayan Database.
Results: While demographics have shifted toward older and less experienced climbers, summit success probabilities have nearly doubled since 1990. Pre-acclimatization via normobaric HC (200–300 hours) effectively reduces the risk of Acute Mountain Sickness (AMS) and permits compressed schedules, thereby mitigating high-altitude cachexia and muscle depletion. Smart monitoring has uncovered critical "silent" risks, such as asymptomatic acquired long QT syndrome in 24% of climbers above 7,900 m. Furthermore, climate change provides a subtle assist through the "thicker air" phenomenon, although weather volatility remains a significant challenge.
Conclusions: Technology has transformed Everest mountaineering into a managed, precision-guided endeavor where safety and success are mediated by innovation rather than innate physiology. The industry should evolve toward mandatory medical screening and risk management standards based on objective telemetry from wearable health devices.

Keywords: Mount Everest, Pre-acclimatization, Hypoxia conditioning, Smart-monitoring Acute mountain sickness, Summit success

1. Introduction

Mount Everest, standing at 8,848 meters, represents the ultimate physiological frontier for human survival (Huey et al., 2020; Matthews et al., 2020). In the past, conquering such extreme elevations was restricted to elite athletes endowed with exceptional natural tolerance to hypoxia and extensive, long-term mountaineering experience (Westhoff et al., 2012). However, contemporary high-altitude mountaineering has experienced a paradigm shift driven primarily by technological innovation rather than mere commercial expansion (Huey et al., 2020; Westhoff et al., 2012). Today, the feasibility of mounting a successful Everest expedition no longer depends strictly on an individual's innate physiological predisposition or a lifetime of high-altitude training. Instead, a suite of advanced technological enablers has emerged, acting as a great equalizer (Huey et al., 2020).

This technological toolkit—comprising advanced pre-acclimatization protocols and real-time smart-monitoring systems—actively compensates for lower individual physiological adaptability and limited technical mountaineering skills (Burtscher et al., 2022, 2026; Jia et al., 2026). Consequently, individuals who traditionally would have been screened out due to poor natural altitude tolerance or a lack of extensive experience can now attempt the summit with a significantly higher probability of success (Huey et al., 2020; Westhoff et al., 2012). By artificially inducing physiological adaptations prior to departure through hypoxia conditioning (HC) and utilizing continuous telemetry to detect early signs of decompensation in the "death zone" (>8,000 m), technology bridges the gap between human biological limitations and the hostile environment (Burtscher et al., 2026; Jia et al., 2026; Szymczak et al., 2021).

Despite these advancements, the fundamental physical reality of extreme altitude remains unforgiving (Cai et al., 2026). Severe hypobaric hypoxia continues to induce Acute Mountain Sickness (AMS), High-Altitude Pulmonary Edema (HAPE), and High-Altitude Cerebral Edema (HACE), while also triggering critical cardiovascular anomalies such as acquired long QT syndrome (Cai et al., 2026; Jia et al., 2026; Pilgrim et al., 2024). At the same time, compressed expedition schedules designed around technological pre-acclimatization aim to mitigate the risks of prolonged exposure, physical exhaustion, and high-altitude cachexia, which is characterized by significant metabolic imbalance and muscle mass depletion (Burtscher et al., 2022; Karpęcka-Gałka & Frączek, 2024).

The objective of this narrative review is to synthesize contemporary evidence (2012–2026) regarding how pre-acclimatization and smart-monitoring technologies function as core drivers of this accessibility shift. By redefining how the human body prepares for and interacts with extreme altitude, these technologies transform high-altitude mountaineering from an exclusive domain of physiological elites into a managed, precision-guided endeavor where safety and summit success are increasingly mediated by innovation (Burtscher et al., 2022, 2026; Jia et al., 2026).

2. Methodology

2.1. Study Design: A comprehensive narrative review methodology was employed to evaluate the evolving landscape of high-altitude preparation, diagnostic monitoring, and safety protocols on Mount Everest. This approach was chosen to facilitate an interdisciplinary synthesis of data across altitude physiology, sports technology, and expedition epidemiology, focusing on how innovation acts as a compensatory mechanism for the demographic shift in modern mountaineering.

2.2. Information Sources and Search Strategy A targeted search of major electronic biomedical and scientific databases—including PubMed, Scopus, and Google Scholar—was performed. The search utilized specific Medical Subject Headings (MeSH) and keyword combinations using Boolean operators: ("Mount Everest" OR "Death Zone") AND ("pre-acclimatization" OR "hypoxia conditioning") AND ("smart-monitoring" OR "wearable technology") AND ("acute mountain sickness" OR "cardiac arrhythmias").

2.3. Eligibility Criteria: Studies, clinical reviews, meta-analyses, and expert position papers published primarily between 2012 and 2026 were evaluated to capture the most recent technological shifts. Articles were selected if they explicitly addressed:

1. Hypoxia conditioning (HC) protocols and their time requirements for AMS prevention.
2. Smart-monitoring and telemetry, specifically continuous physiological tracking (SpO2, ECG) via wearable sensors.
3. Expedition logistics and statistics, including success and mortality rates derived from the Himalayan Database.
4. Pharmacological and nutritional strategies intended as "technological enhancements" in extreme-altitude environments.

Exclusion criteria were applied to filter out studies focused exclusively on low-altitude trekking (below 3,500 m) and purely molecular or biochemical research that did not translate directly into operational interventions [As discussed in turn 11 and 13 of the research process].

2.4. Data Synthesis: From the initial search, 21 key publications were qualitatively synthesized to construct a narrative framework. The analysis evaluated the transition from traditional, time-intensive rotational acclimatization to modern, technology-supported paradigms. Data regarding physiological thresholds, cardiovascular complications (such as acquired long QT syndrome), and pre-exposure risk factors were cross-referenced to establish a cohesive clinical and operational perspective.

3. Results

3.1. Innovations in Preparation: Pre-acclimatization and Hypoxia Conditioning

Traditional acclimatization for Mount Everest has historically relied on a "siege-style" approach, requiring weeks of rotational climbs between Base Camp (5,300 m) and higher camps to stimulate erythropoiesis and ventilatory adjustments (Burtscher et al., 2026). However, the development of normobaric hypoxia conditioning (HC) has introduced a technology-mediated alternative, allowing for simulated high-altitude exposure at sea level (Burtscher et al., 2022).

The efficacy of HC in preventing Acute Mountain Sickness (AMS) is governed by a clear dose-response relationship (Burtscher et al., 2026). A synthesis of current clinical evidence indicates that AMS risk reduction is linearly associated with the cumulative duration of hypoxia exposure (Burtscher et al., 2026). Accumulating approximately 75 hours of HC reduces the subsequent risk of AMS by 50%, while a total dose of 200 to 300 hours can theoretically eliminate the risk for terrestrial ascents up to 6,000 meters (Burtscher et al., 2022, 2026).

Table 1: Relationship between Hypoxia Exposure Duration and AMS Risk Reduction (Adapted from Burtscher et al., 2022; Burtscher et al., 2026)

Cumulative Dose (Hours)	AMS Risk Reduction (%)	Clinical Significance
7 – 16.5	12% – 27%	Minimal respiratory changes detected (Faulhaber et al., 2016; Schommer et al., 2010)
~75	50%	Significant protection for rapid ascent (Dehnert et al., 2014)
200 – 300	~100% (Theoretical)	Optimal protection for ascents up to 6,000 m (Burtscher et al., 2026)

These technological protocols enable "compressed schedules" or "Flash expeditions," which significantly reduce the duration of exposure to the hostile mountain environment (Burtscher et al., 2026). While HC provides a physiological bridge for less-resilient climbers, it does not inherently enhance technical skills or aerobic endurance (Burtscher et al., 2026; Cai et al., 2026). Furthermore, while rapid ascent remains a primary risk factor, individuals who undergo structured pre-acclimatization experience a transition where their initial exposure becomes a protective factor during further ascent to higher elevations (Zhao et al., 2024).

3.2. Innovations in Diagnostics: Smart-monitoring and Wearable Technology

The transition from subjective symptom-based assessment to objective, real-time physiological tracking represents a cornerstone of the technological shift on Mount Everest (Olejarz et al., 2024). Traditionally, diagnosis relied on self-reported scores like the Lake Louise Scale, which are susceptible to individual bias or "summit fever" (Pilgrim et al., 2024).

Modern wearable technologies have demonstrated high diagnostic accuracy in predicting AMS by quantifying peripheral oxygen saturation (SpO2) and maximum oxygen consumption (VO2 max) (Olejarz et al., 2024; Zeng et al., 2024). Additionally, pre-exposure screening has identified insomnia symptoms as a critical independent predictor of AMS risk (Hou et al., 2026). Research using the Athens Insomnia Scale (AIS) revealed that baseline insomnia is significantly associated with AMS onset, with an odds ratio of 3.074 (Hou et al., 2026).

The application of wearable continuous ECG patches has revealed previously "silent" cardiovascular risks in the death zone (Pilgrim et al., 2024). The 2023 SUMMIT study found that 59% of climbers experienced significant QTc prolongation (≥ 60 ms) above 7,900 meters, and 24% developed acquired long QT syndrome (Pilgrim et al., 2024). Critically, many of these life-threatening cardiac events were asymptomatic, meaning climbers remained unaware of their physiological vulnerability while in the death zone (Pilgrim et al., 2024).

3.3. Logistical Infrastructure and Mortality Dynamics

The accessibility of Mount Everest has been fundamentally redefined by a highly developed logistical framework (Huey et al., 2020). Since the 1990–2005 era, the probability of summit success has nearly doubled for both men and women (Huey et al., 2020). This shift is attributed to "collective experience" among commercial operators, the use of extensive fixed-rope infrastructure, and high-flow supplemental oxygen systems (Huey et al., 2020; Westhoff et al., 2012).

Table 2: Temporal Trends in Everest Success and Mortality Rates (Members Only) (Adapted from Huey et al., 2020)

Period	Success Rate (%)	Mortality Rate (Women)	Mortality Rate (Men)
1990–2005	~33%	1.9%	1.7%
2006–2019	~66%	0.5%	1.1%

Despite the demographic shift toward older and less experienced climbers, relative mortality rates have remained stable or declined, suggesting that technology effectively compensates for lower individual physiological masters (Huey et al., 2020). However, crowding at bottlenecks (e.g., Hillary Step) remains a severe hazard, forcing climbers into prolonged static exposure in the death zone, which rapidly depletes oxygen reserves and increases the risk of HAPE and HACE (Huey et al., 2020; Westhoff et al., 2012).

3.4. Environmental Influences and "Thicker Air"

Innovations in meteorological monitoring have highlighted that oxygen availability on Everest is highly sensitive to variations in barometric pressure (Matthews et al., 2020). Swings in pressure can change Everest's perceived elevation by almost 750 meters (Matthews et al., 2020).

A unique technological "assist" is emerging due to climate change: global warming has led to an increase in summit air pressure, effectively making the summit "feel lower" (Matthews et al., 2020). This "thicker air" phenomenon (2.10 hPa per 1°C of warming) may subtly enhance survival probabilities (Matthews et al., 2020). Nevertheless, these gains are often countered by weather extremes, with wind speeds reaching 80 m/s and wind chill temperatures plunging to -65°C (Szymczak et al., 2021).

4. Discussion

4.1. The Great Equalizer: Technology Overcoming Individual Limitations

The findings of this review underscore a fundamental shift in the determinants of success on Mount Everest. Historically, survival and summit success were primarily dictated by individual mountaineering mastery and innate physiological resilience to hypoxia (Westhoff et al., 2012). However, recent epidemiological data reveals a "Safety Paradox": while the demographic of climbers has shifted toward older and less experienced individuals, summit success probabilities have effectively doubled, and relative mortality has remained stable or even declined (Huey et al., 2020).

This trend suggests that the "collective experience" embedded in modern commercial infrastructure—comprising high-flow supplemental oxygen, precision weather forecasting, and extensive fixed-rope networks—acts as a powerful compensatory mechanism (Huey et al., 2020; Westhoff et al., 2012). Technology has effectively widened the margin of error, allowing individuals who would traditionally be screened out by physiological limits to operate within the "death zone" (Burtscher et al., 2026; Matthews et al., 2020). Consequently, Everest mountaineering has transitioned from a feat of individual athletic prowess to a managed industrial endeavor where success is mediated by technological access.

4.2. Precision Pre-acclimatization and the Mitigation of Metabolic Decay

The implementation of normobaric hypoxia conditioning (HC) represents a significant breakthrough in preparing less-resilient climbers for extreme altitudes (Burtscher et al., 2022). The identified dose-response relationship—where a cumulative dose of 200 to 300 hours of simulated hypoxia can theoretically eliminate AMS risk up to 6,000 m—allows for the design of "precision pre-acclimatization" protocols (Burtscher et al., 2026).

Beyond AMS prevention, these technologies facilitate "compressed expedition schedules" (Burtscher et al., 2026). This is of critical clinical importance because traditional multi-week terrestrial acclimatization often leads to high-altitude cachexia, characterized by a significant loss of muscle mass and metabolic instability (Karpęcka-Gałka & Frączek, 2024). By arriving on-site already physiologically "primed," recreational climbers can minimize the period of environmental decay, preserving their physical reserves for the final summit push (Burtscher et al., 2022). Furthermore, initial hypoxia exposure through structured protocols can transform from a risk factor into a protective factor during further ascent (Zhao et al., 2024).

4.3. Diagnostic Revolution: Uncovering the "Silent" Risks

The integration of smart-monitoring technologies has revolutionized risk management by replacing subjective symptom reporting with objective, real-time telemetry (Olejarz et al., 2024). Traditionally, diagnosis relied on clinical scores susceptible to individual bias or the "summit fever" phenomenon (Pilgrim et al., 2024).

The discovery that 59% of climbers develop significant QTc prolongation and 24% develop acquired long QT syndrome above 7,900 m highlights a critical, asymptomatic cardiovascular vulnerability (Pilgrim et al., 2024). The fact that these life-threatening events were asymptomatic emphasizes that even "successful" climbers face silent physiological decompensation that modern wearables can now detect (Pilgrim et al., 2024). Additionally, identifying baseline insomnia as a predictor of AMS (OR = 3.074) suggests that pre-exposure screening via apps and wearables can stratify risk before a climber even reaches base camp (Hou et al., 2026).

4.4. Ethical Considerations of "Enhanced" Mountaineering

The "democratization" of Everest through technology raises complex ethical questions regarding the "spirit of sport" (Gordon & Dodds, 2023). While substances like acetazolamide and dexamethasone are banned in competitive contexts, there is a compelling argument for their use on Everest as essential safety gear rather than doping (Wagner, 2012).

This study supports the concept of "therapeutic exemption," where technology and pharmacology are used to return an individual to a "normal" level of functioning in a hostile environment (Gordon & Dodds, 2023). However, as technology makes the "impossible" accessible, the ethical burden of rescue increases (Ellerton et al., 2026). The mountaineering community must reconcile the increased feasibility of the summit with the escalating risks for professional rescue teams and Sherpas who must respond when technological enablers fail (Dorji et al., 2023; Ellerton et al., 2026).

4.5. Environmental Factors: A Fragile Technological Assist

The review highlights an unexpected synergy between technology and climate change: the "thicker air" phenomenon (Matthews et al., 2020). Rising global temperatures increase summit barometric pressure, effectively making the summit "feel" approximately 100 meters lower and increasing oxygen availability (Matthews et al., 2020). While this provides a subtle environmental assist to summit success, it is tempered by the extreme volatility of weather in the death zone (Szymczak et al., 2021). High-resolution meteorological monitoring is now essential to navigate these conditions, where wind chill can plunge to -65°C despite the increased air pressure (Szymczak et al., 2021).

4.6. Implications for Field Practice and Future Research

The evidence points toward a necessary transition in high-altitude medicine from voluntary self-regulation to a framework of mandatory medical screening and evidence-based fitness standards (Ellerton et al., 2026; Jia et al., 2026). Future research must focus on validating AI-driven predictive models that integrate SpO_2, heart rate variability, and sleep data from wearables to provide early warnings of decompensation (Jia et al., 2026; Olejarz et al., 2024). Additionally, while short-term mountaineering appears to have minimal negative impacts on cognitive function, further studies are needed to evaluate the long-term neurological consequences of repetitive extreme-altitude exposure (Li et al., 2023).

Ultimately, as technology continues to bridge the gap between human biology and the vertical frontier, safety standards must evolve to utilize data-driven diagnostics as the primary tool for risk stratification and ethical accountability (Ellerton et al., 2026; Pilgrim et al., 2024).

5. Conclusion

The evidence synthesized in this review confirms that Mount Everest mountaineering has undergone a fundamental transformation where technological innovation now serves as the primary driver of accessibility and success. While the physical hazards of the "death zone" remain an absolute biological limit, the emergence of advanced preparatory and diagnostic tools has effectively shifted the human physiological frontier (Huey et al., 2020; Matthews et al., 2020).

The key findings indicate that pre-acclimatization via normobaric hypoxia conditioning (HC) is a highly effective, time-compressed alternative to traditional terrestrial rotations, with a cumulative dose of 200 to 300 hours potentially eliminating the risk of Acute Mountain Sickness (AMS) for ascents up to 6,000 meters (Burtscher et al., 2022, 2026). Furthermore, the integration of smart-monitoring technologies has revolutionized risk management by replacing subjective symptom reporting with objective telemetry. These tools have uncovered critical, asymptomatic vulnerabilities, most notably the high prevalence of acquired long QT syndrome above 7,900 meters, which poses a silent threat even to successful climbers (Pilgrim et al., 2024). Epidemiological trends further demonstrate that "collective experience" and logistical infrastructure now compensate for the lower individual mastery of a demographic that is increasingly older and less experienced (Huey et al., 2020; Westhoff et al., 2012). Finally, the "thicker air" phenomenon induced by climate change provides a subtle environmental assist by increasing oxygen availability at the summit, though this is tempered by rising weather volatility (Matthews et al., 2020; Szymczak et al., 2021).

5.1. Directions for Future Research

Despite these advancements, several critical gaps remain that warrant further scientific investigation:

- Validation of Diagnostic Algorithms: Future research should focus on the prospective validation of predictive models for high-altitude illness across more diverse populations, including women and older recreational climbers, to ensure the reliability of wearable-based AMS alerts (Jia et al., 2026; Olejarz et al., 2024).
- Refinement of Hypoxia Protocols: There is a need for well-controlled studies to establish the optimal dose-response relationship for HC combined with pharmacological prophylaxis (such as acetazolamide) to determine if synergistic effects can further enhance safety (Burtscher et al., 2026).
- Neurocognitive and Long-term Impact: Given that short-term mountaineering appears to have minimal negative impacts on cognitive function, future studies should employ standardized test frameworks to evaluate the long-term neurological consequences of repetitive exposure to extreme hypoxia (Li et al., 2023; Olejarz et al., 2024).
- Global Morbidity Registries: Establishing international registries for real-time physiological data collected via wearables would allow for a more nuanced understanding of high-altitude morbidity and the creation of evidence-based medical screening standards (Ellerton et al., 2026; Pilgrim et al., 2024).

Ultimately, as technology continues to "democratize" the world’s highest peaks, the mountaineering industry must transition from a model of individual risk-taking to a data-supported, precision-guided framework that prioritizes evidence-based safety and ethical accountability at the vertical limits of human survival.

Disclosure Section

Conceptualization: Agata Sobczak and Maja Kowalczyk
Methodology: Agata Sobczak, Anna Waldman
Software: Maja Kowalczyk, Kalina Kreft, Magdalena Wolff
Validation: Kalina Kreft, Lena Głuszkiewicz and Anna Waldman
Formal analysis: Anna Waldman, Maja Kowalczyk, Magdalena Wolff
Investigation: Kalina Kreft, Agata Sobczak
Resources: Magdalena Wolff, Agata Sobczak
Data curation: Magdalena Wolff, Kalina Kreft
Writing—original draft preparation: Agata Sobczak, Magdalena Wolff
Writing—review and editing: Maja Kowalczyk, Kalina Kreft, Magdalena Wolff and Lena Głuszkiewicz
Visualization: Magdalena Wolff, Lena Głuszkiewicz
Supervision: Kalina Kreft
Project administration: Lena Głuszkiewicz, Maja Kowalczyk
Funding: The article did not receive any funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Not applicable

All authors have read and agreed to the published version of the manuscript.
The authors declare no conflict of interest.

During the preparation of this manuscript, the authors used AI tools solely for English language editing and stylistic refinement. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the framework and accuracy of the publication.

References

Burtscher, J., Gatterer, H., Beidleman, B. A., Burtscher, M. (2025). Dexamethasone for prevention of AMS, HACE, and HAPE and for limiting impairment of performance after rapid ascent to high altitude: a narrative review. *Military Medical Research*, 12, 48. https://doi.org/10.1186/s40779-025-00634-y

Burtscher, J., Hüfner, K., Gatterer, H., Pichler-Hefti, J., Hefti, U., Tannheimer, M., Kleinsasser, A., Hackett, P., Burtscher, M. (2026). Time requirements of pre-acclimatization at simulated altitude to prevent acute mountain sickness. *Journal of Travel Medicine*, 33(3), taag009.

https://doi.org/10.1093/jtm/taag009

Burtscher, M., Millet, G. P., Burtscher, J. (2022). Hypoxia conditioning for high-altitude pre-acclimatization. *Journal of Science in Sport and Exercise*, 4, 331–345. https://doi.org/10.1007/s42978-021-00150-0

Cai, C., Ni, G., Chen, L., Deng, C., Chai, S., Wang, R., Zhang, R., Luo, F., Ge, R. (2026). Altitude hypoxia and hypoxemia: pathogenesis and management. *Signal Transduction and Targeted Therapy*, 11, 27. https://doi.org/10.1038/s41392-025-02531-1

Choroszewicz, P., Dobosiewicz, A. M., Badiuk, N. (2020). Acetazolamide in the prevention of altitude disease. *Pedagogy and Psychology of Sport*, 6(2), 95–103. https://doi.org/10.12775/PPS.2020.06.02.009

Dorji, T., Giri, S., Tshering, U., LeVine, S., Tshering, U., Chhetri, S., Dhakal, N., Gaikwad, S. N., Flaherty, G. T., Lucero-Prisno III, D. L., McIntosh, S. (2023). Challenges in the management of high-altitude illnesses and emergencies in Bhutan and Nepal. *Travel Medicine and Infectious Disease*, 56, 102660. https://doi.org/10.1016/j.tmaid.2023.102660

Ellerton, J., Sheets, A., McLaughlin, K., Paal, P. (2026). Rescue at extreme altitude: managing the ethical considerations in the language of risk management. An International Commission for Alpine Rescue position paper. *High Altitude Medicine & Biology*, 27(2), 117–122. https://doi.org/10.1177/15578682251400732

Gordon, E. C., Dodds, C. (2023). High altitude, enhancement, and the 'spirit of sport'. *Journal of the Philosophy of Sport*, 50(1), 63–82. https://doi.org/10.1080/00948705.2023.2168679

Hou, S., Jiang, J., Huang, Y., Liang, Y., Zhou, X., Li, L., (2026). The independent predictive effect of insomnia symptoms before high-altitude exposure on acute mountain sickness: an observational study of healthy volunteers at 2726 m. *Frontiers in Psychiatry*, 17, 1765494. https://doi.org/10.3389/fpsyt.2026.1765494

Huey, R. B., Carroll, C., Salisbury, R., Wang, J. L. (2020). Mountaineers on Mount Everest: Effects of age, sex, experience, and crowding on rates of success and death. *PLoS One*, 15(8), e0236919. https://doi.org/10.1371/journal.pone.0236919

Jia, N., Chen, C., Chen, Q., Liu, J., Shen, Z., Liu, Y., Pei, C., Wang, Y., Huang, D., Wang, F., He, Y., Wang, Z. (2026). Acute high-altitude illness: risk factors, susceptibility prediction, and personalized prevention and treatment. *Frontiers in Medicine*, 12, 1735083. https://doi.org/10.3389/fmed.2025.1735083

Karpęcka-Gałka, E., Frączek, B. (2024). Nutrition, hydration, and supplementation considerations for mountaineers in high-altitude conditions: a narrative review. *Frontiers in Sports and Active Living*, 6, 1435494. https://doi.org/10.3389/fspor.2024.1435494

Karpęcka-Gałka, E., Mazur-Kurach, P., Szyguła, Z., Frączek, B. (2023). Diet, supplementation and nutritional habits of climbers in high mountain conditions. *Nutrients*, 15(19), 4219. https://doi.org/10.3390/nu15194219

Li, L., Zhou, Y., Zou, S., Wang, Y. (2023). The effects of high-altitude mountaineering on cognitive function in mountaineers: a meta-analysis. *International Journal of Environmental Research and Public Health*, 20(6), 5101. https://doi.org/10.3390/ijerph20065101

Matthews, T., Perry, L. B., Lane, T. P., Elmore, A. C., Khadka, A., Aryal, D., Shrestha, D., Tuladhar, S., Baidya, S. K., Gajurel, A., Potocki, M., Mayewski, P. A. (2020). Into thick(er) air? Oxygen availability at humans' physiological frontier on Mount Everest. *iScience*, 23, 101718. https://doi.org/10.1016/j.isci.2020.101718

Olejarz, Z., Nowak, K., Drygała, Z., Wyrwał, J., Zielińska, Z., Słowik, M., Nowak, K., Nieć, M., Gierlach, K., Krasuska, M. (2024). Examination of novel diagnostic approaches and contemporary strategies for preventing acute mountain sickness. *Journal of Education, Health and Sport*, 54, 141-157. https://doi.org/10.12775/JEHS.2024.54.011

Pilgrim, T., Ryffel, C., Sherpa, P. P., Sherpa, T., Sherchand, O., Galuszka, O., Odening, K. E., Rothenbuhler, M., Reichlin, T., Sherpa, K. (2024). QT prolongation and acquired long QT syndrome in climbers on Mount Everest. *JACC: Clinical Electrophysiology*, 10(11), 2509–2511. https://doi.org/10.1016/j.jacep.2024.07.012

Szymczak, R. K., Marosz, M., Grzywacz, T., Sawicka, M., Naczyk, M. (2021). Death zone weather extremes mountaineers have experienced in successful ascents. *Frontiers in Physiology*, 12, 696335. https://doi.org/10.3389/fphys.2021.696335

Wagner, D. R. (2012). Medical and sporting ethics of high altitude mountaineering: the use of drugs and supplemental oxygen. *Wilderness & Environmental Medicine*, 23, 205–206. https://doi.org/10.1016/j.wem.2012.03.011

Westhoff, J. L., Koepsell, T. D., & Littell, C. T. (2012). Effects of experience and commercialization on survival in Himalayan mountaineering: retrospective cohort study. *BMJ*, 344, e3782. https://doi.org/10.1136/bmj.e3782

Zhao, C., Zhao, X., Ma, Y., Liu, Y., Chen, R., Sha, L. (2024). Dynamics in the prevalence and clinical manifestations of acute mountain sickness of different ascent protocols during high-altitude exposure. *Frontiers in Public Health*, 12, 1472935. https://doi.org/10.3389/fpubh.2024.1472935